Gnubiotics Sciences Revenue and Competitors
Estimated Revenue & Valuation
- Gnubiotics Sciences's estimated annual revenue is currently $2.8M per year.
- Gnubiotics Sciences's estimated revenue per employee is $155,000
Employee Data
- Gnubiotics Sciences has 18 Employees.
Gnubiotics Sciences's People
Name | Title | Email/Phone |
---|
Gnubiotics Sciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Gnubiotics Sciences?
GNUbiotics is a Swiss company, established in 2016, supplying breakthrough nutritional bio similar oligosaccharides to influence the microbiome and positively impact the gut, for the food and nutrition industries. We are developing a family of MAC (Microbiota Accessible Carbohydrates) to reproduce the natural diversity and benefits of unique structures found in animal and human' milk. MACs are complex carbohydrates that are resistant to digestion by a host's metabolism, and are made available to selected gut bacteria as an energy source. ›Product GNU100: First in-class microbiome modulating prebiotic for animal feed to be integrated into new pet food recipes to rebalance pets' microbiota naturally. Unique rich source of oligosaccharides, containing up to 30 different structures, including sialylated glycans, that can potentially shape intestinal microbiota for gut protection.
keywords:N/AN/A
Total Funding
18
Number of Employees
$2.8M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Gnubiotics Sciences News
Glycopeptides are the foundation of Gnubiotics' GLAAD molecules. GLAAD relies on glycopeptides as providers of antigenicity and adjuvanticity to...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $8.3M | 33 | N/A | N/A |
#2 | $6.2M | 40 | -33% | N/A |
#3 | $11.9M | 52 | 27% | N/A |
#4 | $28.8M | 187 | 32% | N/A |